Abstract
Neuronal cell specific cyclin-dependent kinase 5 (Cdk5) is a known regulator of neurodegenerative disorders such as Alzheimers and Parkinsons diseases. We report that Cdk5 also plays an important role in the proliferation of breast cancer cells MCF-7 and MDA MB-231 and is functionally involved in chemosensitivity as well as in cell death pathways induced by anti-cancer drug carboplatin (Carb). Here, we demonstrate that carboplatin induced Cdk5 activation under positive regulation of ERK, promotes cell death in MCF-7 and MDA MB-231 cells. DNA-damage stress enhanced ERK activity utilizes Cdk5 as one of its downstream targets for the execution of death signal in carboplatin induced death in MCF-7 and MDA MB-231 cells. Additionally, present data clearly indicates that activated Cdk5 modulates p53 transactivation in MCF-7 cells. However, in p53 mutant MDA MB-231 cells, Cdk5 mediated cell death is likely to be p53 independent. Collectively, our findings not only draw attention to the extra-neuronal functions of Cdk5 but also propose Cdk5 as a novel and potential therapeutic target of chemotherapeutic drugs.
Keywords: Carboplatin, Cdk5, ERK, p53
Current Cancer Drug Targets
Title: Cell Cycle Regulatory Protein 5 (Cdk5) is a Novel Downstream Target of ERK in Carboplatin Induced Death of Breast Cancer Cells (Supplementary Data)
Volume: 8 Issue: 8
Author(s): Ankur Kumar Upadhyay, Amrendra Kumar Ajay, Sandeep Singh and Manoj Kumar Bhat
Affiliation:
Keywords: Carboplatin, Cdk5, ERK, p53
Abstract: Neuronal cell specific cyclin-dependent kinase 5 (Cdk5) is a known regulator of neurodegenerative disorders such as Alzheimers and Parkinsons diseases. We report that Cdk5 also plays an important role in the proliferation of breast cancer cells MCF-7 and MDA MB-231 and is functionally involved in chemosensitivity as well as in cell death pathways induced by anti-cancer drug carboplatin (Carb). Here, we demonstrate that carboplatin induced Cdk5 activation under positive regulation of ERK, promotes cell death in MCF-7 and MDA MB-231 cells. DNA-damage stress enhanced ERK activity utilizes Cdk5 as one of its downstream targets for the execution of death signal in carboplatin induced death in MCF-7 and MDA MB-231 cells. Additionally, present data clearly indicates that activated Cdk5 modulates p53 transactivation in MCF-7 cells. However, in p53 mutant MDA MB-231 cells, Cdk5 mediated cell death is likely to be p53 independent. Collectively, our findings not only draw attention to the extra-neuronal functions of Cdk5 but also propose Cdk5 as a novel and potential therapeutic target of chemotherapeutic drugs.
Export Options
About this article
Cite this article as:
Upadhyay Kumar Ankur, Ajay Kumar Amrendra, Singh Sandeep and Bhat Kumar Manoj, Cell Cycle Regulatory Protein 5 (Cdk5) is a Novel Downstream Target of ERK in Carboplatin Induced Death of Breast Cancer Cells (Supplementary Data), Current Cancer Drug Targets 2008; 8 (8) . https://dx.doi.org/10.2174/156800908786733405
DOI https://dx.doi.org/10.2174/156800908786733405 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Generalized String Pseudo-Folding Lattices in Bioinformatics: State-of-Art Review, New Model for Enzyme Sub-Classes, and Study of ESTs on Trichinella spiralis
Current Bioinformatics The Molecular Targets of Cannabinoids in the Treatment of Cancer and Inflammation
Current Pharmaceutical Design Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies
Current Medicinal Chemistry Nanoparticle Therapy for Allergic and Inflammatory Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Synthesis of New Ligands Derived from Polyphosphonates Partial Esters
Letters in Organic Chemistry Novel Fluorescent Benzimidazoles: Synthesis, Characterization, Crystal Structure and Evaluation of Their Anticancer Properties
Letters in Organic Chemistry Update on Statins: Hope for Osteoporotic Fracture Healing Treatment
Current Drug Targets Synthesis of Isoxazole Moiety Containing Thieno[2,3-d]pyrimidine Derivatives and Preliminarily in vitro Anticancer Activity (Part II)
Anti-Cancer Agents in Medicinal Chemistry Near-infrared Light Activatable Multimodal Gold Nanostructures Platform: An Emerging Paradigm for Cancer Therapy
Current Cancer Drug Targets Pharmacogenetics and Inflammatory Bowel Disease
Current Pharmacogenomics and Personalized Medicine Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Current Pharmaceutical Design The Diagnostic Utility of Pleural Fluid Tests in Clinical Practice
Current Respiratory Medicine Reviews Recent Development in Indole Derivatives as Anticancer Agents for Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Antibodies and Other Proteins Obtained by Molecular Display Technologies
Recent Patents on Biotechnology Breaking the Barrier of Cancer Through Liposome Loaded with Phytochemicals
Current Drug Delivery The Role of Anti-LeY Antibody in the Downregulation of MAPKs/COX-2 Pathway in Gastric Cancer
Current Drug Targets Use of Gadoxetic Acid-enhanced MRI to Predict the Development of Postoperative Pancreatic Fistulas by Estimating the Degree of Pancreatic Fibrosis
Current Medical Imaging Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and <i>in vitro</i> Studies
Current Cancer Drug Targets Non-Analgesic Effects of Opioids: Neuroprotection in the Retina
Current Pharmaceutical Design Targeting Allosteric Control Mechanisms in Heat Shock Protein 70 (Hsp70)
Current Topics in Medicinal Chemistry